Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy
NCT ID: NCT01645098
Last Updated: 2015-02-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53 participants
INTERVENTIONAL
2011-08-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT02740972
Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons
NCT00451074
Finding the Optimum Regimen for Duchenne Muscular Dystrophy
NCT01603407
Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular Dystrophy
NCT01451281
Safety and Efficacy of P-188 NF in DMD Patients
NCT03558958
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexmedetomidine 1 mcg/kg
Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
Ketamine
1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine
0.5 mcg/kg/hr IV
Dexmedetomidine 0.5 mcg/kg
Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
Ketamine
1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine
0.5 mcg/kg/hr IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketamine
1 mg/kg IV, additional doses of 0.5 mg/kg as needed
Dexmedetomidine
0.5 mcg/kg/hr IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nationwide Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph D. Tobias
Chairman, Dept. of Anesthesiology & Pain Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph D Tobias, MD
Role: PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nationwide Children's Hospital
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB11-00532
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.